Not every protein-protein interaction impacts cancer drug design

Researchers uncover a detailed action mechanism for protein MRG15, an important consideration for drugs targeting ASH1L which is overexpressed in many cancers. The findings from King Abdullah University of Science and Technology (KAUST), Saudi Arabia and the University of Michigan, U.S, could implicate the design of future cancer treatments.

African Pharmaceutical Market is expected to see a Double-Digit Growth by 2027 – Emerging Growth Opportunities in Africa

Rapidly growing African population and urbanization, an increasing number of chronic diseases, and growing healthcare spending's are some of the primary factors driving the growth of the African pharmaceutical market.

Revvity Signals Software and Scitara Expand Strategic Relationship to Accelerate Laboratory Digital Transformation

Thermo Fisher Scientific Introduces New Liquid Chromatography Detector

Huateng Pharma Announced To Attend CPhI Korea in August 2023

Huateng Pharma is a leading and professional manufacturer which can provide pharmaceutical intermediates, PEG derivatives, biochemical reagents, APIs, Vitamin D Derivatives and so on. We have a 34,000 square meter manufacturing site with advanced design concept of intelligent manufacturing, which can realize the integration of the production process and accomplish the complete transformation of lab scale - pilot plant - large-scale commercial production, with an annual capacity of more than 1 billion RMB. Hunan Huateng Pharmaceutical Co. Ltd. Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China Email: sales@huatengusa.com Website: https://us.huatengsci.com Zip code: 410205 Telephone: +86 731 89916275 Fax: +86 0731-82251112-818

Samsung Biologics Reports Second Quarter 2023 Financial Results

Recent Cash Injection Boosts VectorBuilder to Unicorn Status

VectorBuilder, a leading gene delivery technology company, announced with its latest cash injection that it reached a $1 billion valuation. VectorBuilder offers a full spectrum of gene delivery solutions covering virtually all research and clinical needs from bench to bedside. It is also a full-service CRO and CDMO supporting customers in their entire drug discovery pipeline, with over 4000 institutional customers worldwide. Gene delivery technologies enable precise manipulation of genetic information in cells and organisms. Besides being the workhorse of life sciences research for many decades, gene delivery technologies can correct genetic disorders, develop personalized medicine, and even enhance crop yields. This has sparked tremendous interest among scientists, clinicians, and industry leaders, making it a sought-after area of innovation and investment.

Biovian announces over €50 million investment in manufacturing facility in Turku, Finland

Biovian, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, has announced a major investment of over €50 million to expand its manufacturing facility in Turku, Finland.

Pharma CEOs pen open letter calling suppliers to commit to sustainability targets

Signed by the CEOs of AstraZeneca, GSK, Merck, Novo Nordisk, Sanofi, Samsung Biologics, and the Chairman of Roche, the Health Systems Task Force is calling on suppliers to commit to joint, minimum climate and sustainability targets.

TransCure bioServices expands reach into APAC with Preclina Inc partnership

TransCure bioServices has expanded its reach in the APAC region by signing a strategic partnership with leading South Korean preclinical research company Preclina Inc.

CD Genomics Launches Advanced Whole Exome Sequencing Service, Empowering Genetic Research

CD Genomics Unveils Cutting-edge DAP-Seq Service Revealing the Hidden Secrets of DNA

CD Genomics Redefines Genomic Research with Full-Length Transcripts Sequencing (Iso-Seq)

BioIVT to Discuss its Pivotal Role in Liquid Biopsy Research at the AACC Annual Scientific Meeting and Clinical Lab Expo

BioIVT’s standardized collection protocols and diverse donor base help facilitate molecular biomarker validation and ensure their clinical utility.

Insilico Medicine Is Developing New Inhalable Formulation of First Generative AI Drug

On the heels of the announcement of Phase II clinical trials for the first generative AI drug for the devastating lung disease idiopathic pulmonary fibrosis (IPF), clinical-stage drug discovery biotech Insilico Medicine has announced another breakthrough – an inhalation solution for its anti-fibrotic small molecule inhibitor designed to give patients in need another treatment option.

Integrated DNA Technologies Launches New Respiratory Virus Panel

Integrated DNA Technologies is revealing a new next generation sequencing (NGS) solution, the xGen™ Respiratory Virus Amplicon Panel, to support researchers as they combat the challenging diseases of today and prepare for the next pathogen of tomorrow. With 98.7% total genomic coverage of viral respiratory variants Respiratory Syncytial Virus (RSV) A, RSV B, Influenza A H1N1, Influenza A H3N2, Influenza B, and SARS-CoV-2, the uniquely configured single panel is designed to monitor the evolution and spread of these six viruses.

Absolute Biotech Relaunches SCICONS™ dsRNA Antibodies and ELISA Kits

The gold standard in dsRNA detection now available to virology researchers worldwide

Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis

TVM Capital Life Science together withTillotts Pharma has announced that the companies will jointly invest up to USD 28 million in the newly formed U.S.-based biotechnology company, Mage Biologics Inc.

Genedata Announces Licensing Agreement with Gilead Sciences to Enhance Data Science Innovation in Discovery Research

GenHealth.AI Accelerates into Healthcare AI Market with New Funding, Advisor Appointments and Use Cases Across Healthcare

AI Start-up Pioneering Generative AI for Healthcare Receives $13M in Early Funding, Adds Industry Luminaries as Advisors, and Kicks off Use Cases for Health Insurance Plans and Provider Systems